How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,900 results for

Benign Prostatic Hyperplasia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

281. Holmium laser enucleation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia [Cochrane protocol]

Holmium laser enucleation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

282. Prostatic Artery Embolization (PAE) for Treatment of Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) Using Bead Block Microspheres

Prostatic Artery Embolization (PAE) for Treatment of Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) Using Bead Block Microspheres Prostatic Artery Embolization (PAE) for Treatment of Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) Using Bead Block Microspheres - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study (...) Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Prostatic Artery Embolization (PAE) for Treatment of Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) Using Bead Block Microspheres The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care

2017 Clinical Trials

283. Prostate Artery Embolization for the Treatment of Symptomatic Benign Prostatic Hyperplasia

Prostate Artery Embolization for the Treatment of Symptomatic Benign Prostatic Hyperplasia Prostate Artery Embolization for the Treatment of Symptomatic Benign Prostatic Hyperplasia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more (...) studies before adding more. Prostate Artery Embolization for the Treatment of Symptomatic Benign Prostatic Hyperplasia The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03055624 Recruitment Status : Completed First Posted : February 16, 2017 Last Update Posted : February 20, 2019 Sponsor: University

2017 Clinical Trials

284. Prostate Artery Embolization for the Treatment of Benign Prostatic Hyperplasia

Prostate Artery Embolization for the Treatment of Benign Prostatic Hyperplasia Prostate Artery Embolization for the Treatment of Benign Prostatic Hyperplasia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Prostate Artery Embolization for the Treatment of Benign Prostatic Hyperplasia The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03179228 Recruitment Status : Withdrawn (FDA approved Embospheres for prostate embolization, so IDE not needed) First Posted : June 7, 2017 Last Update Posted : October 17, 2017

2017 Clinical Trials

285. Whole-genome gene expression analysis in urine samples of patients with prostate cancer and benign prostate hyperplasia. (Abstract)

Whole-genome gene expression analysis in urine samples of patients with prostate cancer and benign prostate hyperplasia. There is an urgent need to find new biomarkers with higher specificity and sensitivity for using early detection of prostate cancer (PrCa) and reducing recurrent unnecessary biopsy rates, psychological and physical stress on the patient, and costs. Being noninvasive, urine-based tests might be suitable in routine practice. The aim of this study was to report the first whole (...) -genome gene expression analysis in urine samples, as noninvasive method, that were obtained from PrCa, benign prostate hyperplasia (BPH), and control groups by using the microarray system from Turkey, to our knowledge.Whole-genome gene expression profiling was conducted in urine samples of 25 patients with PrCa, 24 patients with BPH, and 11 healthy males by using the Illumina Hi Scan microarray system.The number of probes showing a significant change at the level of expression were 101 and 75 in PrCa

2017 Urologic oncology

286. Patterns of Benign Prostate Hyperplasia Based on Magnetic Resonance Imaging are Correlated with Lower Urinary Tract Symptoms and Continence in Men Undergoing a Robot-Assisted Radical Prostatectomy for Prostate Cancer. (Abstract)

Patterns of Benign Prostate Hyperplasia Based on Magnetic Resonance Imaging are Correlated with Lower Urinary Tract Symptoms and Continence in Men Undergoing a Robot-Assisted Radical Prostatectomy for Prostate Cancer. To investigate the association between benign prostatic hyperplasia (BPH) patterns, classified by magnetic resonance imaging (MRI), with lower urinary tract symptoms (LUTS) or continence, preoperatively and after robot-assisted laparoscopic radical prostatectomy (RARP (...) ).This retrospective study included 49 prostate cancer patients, with prostate size >47 cm3, who underwent an endorectal MRI followed by RARP. Five BPH patterns were identified according to Wasserman, and additional prostate measurements were recorded. LUTS were assessed using the International Prostate Symptom Score and the PR25-LUTS-Questionnaire score. Continence was assessed using the International Consultation of Incontinence Questionnaire-Short Form.BPH pattern 3 (44.9%) was identified most common, followed

2017 Urology

287. Relationship of oestrogen receptor alpha gene polymorphisms with risk for benign prostatic hyperplasia and prostate cancer in Chinese men. Full Text available with Trip Pro

Relationship of oestrogen receptor alpha gene polymorphisms with risk for benign prostatic hyperplasia and prostate cancer in Chinese men. The relationship of oestrogen receptor with benign prostatic hyperplasia (BPH) and prostate cancer (PC) is not clear at present. This study aimed to investigate the molecular mechanism underlying the occurrence and development of BPH and prostate.Two hundred forty-four PC cases, 260 BPH patients, and 222 healthy men were recruited from Han people in China (...) ), but men with haplotype TA and enlarged prostate had a low risk for PC (OR = 0.708, 95% CI: 0.551-0.912).These results show the relationship between ESRα gene polymorphism and susceptibility to PC and BPH in Chinese men, and the ethnic and regional difference as well.

2017 Medicine

288. Laser treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia

Laser treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia 2 Avenue du Stade de France – 93218 Saint-Denis La Plaine CEDEX, France Tel.: +33(0) 1 55 93 70 00 – Fax: 33(0) 1 55 93 74 35 – contact.seap@has-sante.fr - www.has-sante.fr INAHTA brief Title Laser treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia Agency HAS, French National Authority for Health (Haute Autorité de Santé) 2 avenue du Stade de France – F 93218 La (...) Plaine Cedex, France Tel: + 33 (0) 1 55 93 70 00 – Fax: + 33 (0) 1 55 93 74 35, contact.seap@has-santé.fr, www.has-sante.fr Reference ISBN number: 978-2-11-138068-4 http://www.has-sante.fr/portail/jcms/c_827591/fr/traitement-des-symptomes-du-bas-appareil- urinaire-lies-a-lhypertrophie-benigne-de-la-prostate-par-laser-rapport-devaluation- technologique Aim To assess and compare the efficacy, the safety and the cost of the laser techniques most widely used in France (laser photoselective vaporisation

2013 Haute Autorite de sante

289. Re: Open Suprapubic versus Retropubic Prostatectomy in the Treatment of Benign Prostatic Hyperplasia during Resident's Learning Curve: A Randomized Controlled Trial. (Abstract)

Re: Open Suprapubic versus Retropubic Prostatectomy in the Treatment of Benign Prostatic Hyperplasia during Resident's Learning Curve: A Randomized Controlled Trial. 29059728 2017 10 24 1527-3792 198 5 2017 Nov The Journal of urology J. Urol. Re: Open Suprapubic versus Retropubic Prostatectomy in the Treatment of Benign Prostatic Hyperplasia during Resident's Learning Curve: A Randomized Controlled Trial. 955-957 S0022-5347(17)77287-4 10.1016/j.juro.2017.08.022 Kaplan Steven A SA eng Journal

2017 The Journal of urology Controlled trial quality: uncertain

290. Effects of Serenoa repens Alcohol Extract on Benign Prostate Hyperplasia. Full Text available with Trip Pro

Effects of Serenoa repens Alcohol Extract on Benign Prostate Hyperplasia. An increasing tendency has recently emerged for the use of phytotherapeutic agents as alternative to commercial pharmacological agents for the treatment of benign prostate hyperplasia (BPH). The purpose of this study is to evaluate the effects of Serenoa repens alcohol extract treatment on BPH patients' symptoms and major parameters during one-year follow-up. The study was performed on 70 men aged 40 - 79 years (mean (...) 60.58) with symptomatic BPH that were divided into a group of 40 patients treated with Serenoa repens extract (SRT) and a control group of 30 patients that received no treatment and were observed only. The following parameters were determined at the time of diagnosis (baseline), and after 6 and 12 months: prostate size, serum prostate-specific antigen (PSA) and uroflowmetry parameters including maximum flow rate (MFR), average flow rate (AFR) and post-voiding residual volume (PVRV). In addition

2017 Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki)

291. Efficacy and safety of combination therapy with tamsulosin, dutasteride and imidafenacin for the management of overactive bladder symptoms associated with benign prostatic hyperplasia: A multicenter, randomized, open-label, controlled trial (DIrecT Study) Full Text available with Trip Pro

Efficacy and safety of combination therapy with tamsulosin, dutasteride and imidafenacin for the management of overactive bladder symptoms associated with benign prostatic hyperplasia: A multicenter, randomized, open-label, controlled trial (DIrecT Study) To evaluate the efficacy and safety of a combination therapy with dutasteride and imidafenacin in patients with benign prostatic hyperplasia and persistent overactive bladder symptoms.A total of 163 patients presenting an enlarged prostate (...) (95% confidence interval -3.72 to -2.52) in the tamsulosin, dutasteride and imidafenacin group. The tamsulosin, dutasteride and imidafenacin group significantly improved total overactive bladder symptom score at week 24 as compared with the tamsulosin and dutasteride group; the mean difference was -1.18 (-2.02 to -0.34). The between-group difference was statistically significant as early as week 4. The total International Prostate Symptom Score, storage subscore, quality of life index, and benign

2017 International journal of urology : official journal of the Japanese Urological Association Controlled trial quality: predicted high

292. Safety and efficacy of the combination of once-daily tadalafil and alpha-1 blocker in Japanese men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A randomized, placebo-controlled, cross-over study. Full Text available with Trip Pro

Safety and efficacy of the combination of once-daily tadalafil and alpha-1 blocker in Japanese men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A randomized, placebo-controlled, cross-over study. To evaluate the safety and efficacy of tadalafil plus α1 -blocker combination therapy in Japanese patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.The present multicenter, randomized, double-blind, placebo-controlled, two-period (...) and an α1 -blocker seems to be safe and well tolerated in Japanese patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Adding tadalafil to baseline α1 -blocker therapy does not translate in adverse effects on the blood pressure. Patients tend to prefer combination therapy over monotherapy, and there seems to be a clinical benefit when using combination therapy.© 2017 The Japanese Urological Association.

2017 International journal of urology : official journal of the Japanese Urological Association Controlled trial quality: uncertain

293. Editorial Comment on "Erectile and Ejaculatory Function Preserved With Convective Water Vapor Energy Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Randomized Controlled Study". (Abstract)

Editorial Comment on "Erectile and Ejaculatory Function Preserved With Convective Water Vapor Energy Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Randomized Controlled Study". 27215687 2017 12 08 2018 12 02 1743-6109 13 6 2016 06 The journal of sexual medicine J Sex Med Editorial Comment on "Erectile and Ejaculatory Function Preserved With Convective Water Vapor Energy Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia (...) Prostatic Hyperplasia Steam 2016 04 21 2016 04 22 2016 5 25 6 0 2016 5 25 6 0 2017 12 9 6 0 ppublish 27215687 S1743-6095(16)30178-3 10.1016/j.jsxm.2016.04.076

2017 The journal of sexual medicine Controlled trial quality: uncertain

294. Response and Rebuttal to Editorial Commentary on "Erectile and Ejaculatory Function Preserved With Convective Water Vapor Energy Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Randomized Controlled Study". (Abstract)

Response and Rebuttal to Editorial Commentary on "Erectile and Ejaculatory Function Preserved With Convective Water Vapor Energy Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Randomized Controlled Study". 27215688 2017 12 08 2018 12 02 1743-6109 13 6 2016 06 The journal of sexual medicine J Sex Med Response and Rebuttal to Editorial Commentary on "Erectile and Ejaculatory Function Preserved With Convective Water Vapor Energy Treatment of Lower Urinary (...) Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Randomized Controlled Study". 936-7 10.1016/j.jsxm.2016.05.002 S1743-6095(16)30192-8 McVary Kevin T KT Division of Urology, Southern Illinois University School of Medicine, Springfield, IL. Electronic address: kmcvary@siumed.edu. Gange Steven N SN Western Urologic Clinic, Salt Lake City, Utah. Gittelman Marc C MC South Florida Medical Research, Aventura, Florida. Goldberg Kenneth A KA Texas Urology, Carrollton, Texas. Patel Kalpesh K Arizona

2017 The journal of sexual medicine Controlled trial quality: uncertain

295. Effect of sildenafil citrate in testosterone induced benign prostate hyperplasia rat model Full Text available with Trip Pro

Effect of sildenafil citrate in testosterone induced benign prostate hyperplasia rat model Efficacy of treatments for benign prostate hyperplasia (BPH) is limited because the disease has complex etiopathogenesis. Recent studies have demonstrated the presence of phosphodiesterase-5 (PDE-5) receptors in prostate tissue. We investigated efficacy of sildenafil citrate in testosteron - induced BPH in rats.The rats were divided into three groups. Each groups had 7 rats. Group 1 was control group (...) . Testosteron propionate 3 mg/kg/day was injected subcutaneously for two weeks in Group 2. The same procedure was done for Group 3 and sildenafil citrate was added to water at daily doses of 2 mg/kg for two weeks. The rats were euthanized with intraperitoneal pentobarbital. The body weights were measured and the prostates were removed.The mean weights of rats were 288±31.93, 345±23.23 and 294±32.86 g in Groups 1, 2 and 3, respectively. The mean prostate weights of rats were 0.74±0.18, 1.3±0.13 and 0.72±0.24

2017 Turkish journal of urology

296. The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia Full Text available with Trip Pro

The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia Benign prostatic hyperplasia (BPH) is characterized by an enlarged prostate, lower urinary tract symptoms (LUTS), and a decreased urinary flow rate. Common in older men, BPH is a progressive disease that can eventually lead to complications including acute urinary retention (AUR) and the need for BPH-related surgery. Both normal and abnormal prostate growth is driven by the androgen dihydrotestosterone (DHT (...) ), which is formed from testosterone under the influence of 5-alpha reductase. Thus, 5-alpha reductase inhibitors (5-ARIs) effectively reduce the serum and intraprostatic concentration of DHT, causing an involution of prostate tissue. Two 5-ARIs are currently available for the treatment of BPH-finasteride and dutasteride. Both have been demonstrated to decrease prostate volume, improve LUTS and urinary flow rates, which ultimately reduces the risk of AUR and BPH-related surgery. Therefore, either alone

2017 Asian Journal of Urology

297. Botulinum toxin and benign prostatic hyperplasia Full Text available with Trip Pro

Botulinum toxin and benign prostatic hyperplasia Benign prostatic hyperplasia (BPH) is a clinical condition where lower urinary tract symptoms are caused by both a physically obstructing prostate as well as tight smooth muscles around the bladder outlet. Treatment of this condition with botulinum toxin has been used since 2003, but this interest has somewhat died down after two large randomized controlled trials (RCTs) showing equivalence of results between their treatment and placebo arms

2017 Asian Journal of Urology

298. Genetic alterations in benign prostatic hyperplasia patients Full Text available with Trip Pro

Genetic alterations in benign prostatic hyperplasia patients Background: Benign prostate hyperplasia (BPH) is a classical age-related disease of the prostate, present in 20% of men at the age of 40 years with progression to 70% by the age of 60 years. BPH is associated with various lower urinary tract symptoms, which affect their day-to-day life. Materials and methods: Our objective was to evaluate the association between HER-2/neu, c-myc, p53, and clinicopathological variables in 45 patients (...) diagnosed with benign prostatic hyperplasia using fluorescence in situ hybridization (FISH). The patients underwent transurethral prostate resection to address their primary urological problem. All patients were evaluated by use of a comprehensive medical history and rectal digital examination. The preoperative evaluation also included serum prostate specific antigen (PSA) measurement and ultrasonographic measurement of prostate volume. Results: The mean (± standard deviation) age of the 45 patients

2017 GMS German Medical Science

299. Potential of Moringa oleifera in the Treatment of Benign Prostate Hyperplasia: Role of Antioxidant Defence Systems Full Text available with Trip Pro

Potential of Moringa oleifera in the Treatment of Benign Prostate Hyperplasia: Role of Antioxidant Defence Systems This study sought to evaluate the protective effect of ethanolic leaf extract of Moringa oleifera on testosterone-induced benign prostatic hyperplasia (BPH) in male Sprague-Dawley rats.BPH was induced in rats by the administration of testosterone propionate (3 mg/kg, s.c., in olive oil) for 4 weeks. M. oleifera (50, 100, or 200 mg/kg), celecoxib (20 mg/kg), or M. oleifera (50 mg/kg (...) ) + celecoxib (20 mg/kg) were orally administered daily 15 min before testosterone. On day 29, blood was collected to measure the levels of serum testosterone and prostate-specific antigen before the animals were sacrificed. The prostates were weighed, assayed, and histologically examined.M. oleifera significantly reduced the testosterone-induced increase in prostate weight (20.16%), prostate index (65.85%), serum testosterone (72.86%), and prostate-specific antigen (48.49%). Testosterone caused

2017 Medical Principles and Practice

300. Cost-effectiveness analysis of six therapies for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia Full Text available with Trip Pro

Cost-effectiveness analysis of six therapies for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia To conduct a cost-effectiveness analysis from payers' perspectives of six treatments for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) and to examine positioning of these modalities in the marketplace for the best use of health care funds and quality-of-life benefits for patients.The economic analysis was conducted (...) with a Markov model to compare combination prescription drug therapy (ComboRx), minimally invasive therapies (MITs) including convective radiofrequency (RF) water vapor thermal therapy (Rezūm®), conductive RF thermal therapy (Prostiva®), and prostatic urethral lift (UroLift®), and invasive surgical procedures including photovaporization of the prostate (Greenlight® PVP) and transurethral resection of the prostate (TURP). Effects assessed with International Prostate Symptom Score, adverse events, and re

2017 ClinicoEconomics and Outcomes Research: CEOR

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>